Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
about
Feasibility of using marginal liver grafts in living donor liver transplantation.Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Nonintervention
P2860
Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Risk of hepatitis B reactivati ...... for lymphoma: a meta-analysis.
@en
type
label
Risk of hepatitis B reactivati ...... for lymphoma: a meta-analysis.
@en
prefLabel
Risk of hepatitis B reactivati ...... for lymphoma: a meta-analysis.
@en
P2093
P2860
P1476
Risk of hepatitis B reactivati ...... for lymphoma: a meta-analysis.
@en
P2093
Dongping Xu
Shunquan Wu
Xiaodong Li
Zilin Tang
P2860
P2888
P356
10.1007/S12072-017-9817-Y
P577
2017-08-30T00:00:00Z
P6179
1091399556